JPWO2021235293A1 - - Google Patents
Info
- Publication number
- JPWO2021235293A1 JPWO2021235293A1 JP2022524409A JP2022524409A JPWO2021235293A1 JP WO2021235293 A1 JPWO2021235293 A1 JP WO2021235293A1 JP 2022524409 A JP2022524409 A JP 2022524409A JP 2022524409 A JP2022524409 A JP 2022524409A JP WO2021235293 A1 JPWO2021235293 A1 JP WO2021235293A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026001566A JP2026065050A (ja) | 2020-05-20 | 2026-01-07 | Ｃｕｇリピート配列の結合剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020088499 | 2020-05-20 | ||
| PCT/JP2021/018079 WO2021235293A1 (ja) | 2020-05-20 | 2021-05-12 | Ｃｕｇリピート配列の結合剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026001566A Division JP2026065050A (ja) | 2020-05-20 | 2026-01-07 | Ｃｕｇリピート配列の結合剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2021235293A1 true JPWO2021235293A1 (https=) | 2021-11-25 |
Family
ID=78708927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524409A Pending JPWO2021235293A1 (https=) | 2020-05-20 | 2021-05-12 | |
| JP2026001566A Pending JP2026065050A (ja) | 2020-05-20 | 2026-01-07 | Ｃｕｇリピート配列の結合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026001566A Pending JP2026065050A (ja) | 2020-05-20 | 2026-01-07 | Ｃｕｇリピート配列の結合剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230193265A1 (https=) |
| EP (1) | EP4154886A4 (https=) |
| JP (2) | JPWO2021235293A1 (https=) |
| WO (1) | WO2021235293A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3216313A1 (en) * | 2021-04-30 | 2022-11-03 | Masayuki NAKAMORI | Myotonic dystrophy type 1 therapeutic drug |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140050778A1 (en) * | 2010-12-28 | 2014-02-20 | University Of Rochester | Nucleic acid binding compounds, methods of making, and use thereof |
| US20160206753A1 (en) * | 2013-08-29 | 2016-07-21 | The Scripps Research Institute | Modularly assembled small molecules for the treatment of myotonic dystrophy type 1 |
| JP2019514938A (ja) * | 2016-04-27 | 2019-06-06 | サミュメッド リミテッド ライアビリティ カンパニー | イソキノリン−３イル−カルボキサミドならびにその調製および使用の方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
-
2021
- 2021-05-12 US US17/925,225 patent/US20230193265A1/en active Pending
- 2021-05-12 WO PCT/JP2021/018079 patent/WO2021235293A1/ja not_active Ceased
- 2021-05-12 EP EP21809693.1A patent/EP4154886A4/en active Pending
- 2021-05-12 JP JP2022524409A patent/JPWO2021235293A1/ja active Pending
-
2026
- 2026-01-07 JP JP2026001566A patent/JP2026065050A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140050778A1 (en) * | 2010-12-28 | 2014-02-20 | University Of Rochester | Nucleic acid binding compounds, methods of making, and use thereof |
| US20160206753A1 (en) * | 2013-08-29 | 2016-07-21 | The Scripps Research Institute | Modularly assembled small molecules for the treatment of myotonic dystrophy type 1 |
| JP2019514938A (ja) * | 2016-04-27 | 2019-06-06 | サミュメッド リミテッド ライアビリティ カンパニー | イソキノリン−３イル−カルボキサミドならびにその調製および使用の方法 |
Non-Patent Citations (4)
| Title |
|---|
| LOPEZ-MORATO M. ET AL.: "Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1", FRONTIERS IN NEUROLOGY, vol. 9, JPN6021020916, 2018, pages 349, ISSN: 0005567687 * |
| MATSUMOTO J. ET AL.: "The Dimeric Form of 1,3-Diaminoisoquinoline Derivative Rescued the Mis-splicing of Atp2a1 and Clcn1", CHEMISTRY-A EUROPIAN JOURNAL, vol. 26, JPN6021020920, 25 May 2020 (2020-05-25), pages 14305 - 14309, ISSN: 0005567689 * |
| REDDY K. ET AL.: "Mitigating RNA Toxicity in Myotonic Dystrophy using Small Molecules", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, JPN6021020918, 2019, pages 4017, ISSN: 0005567688 * |
| VO T. ET AL.: "Biosensor-surface plasmon resonance: A strategy to help establish a new generation RNA-specific smal", METHODS, vol. 167, JPN6021020914, 2019, pages 15 - 27, ISSN: 0005567686 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230193265A1 (en) | 2023-06-22 |
| WO2021235293A1 (ja) | 2021-11-25 |
| EP4154886A4 (en) | 2023-11-08 |
| EP4154886A1 (en) | 2023-03-29 |
| JP2026065050A (ja) | 2026-04-14 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240401 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20241226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250606 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260107 |